Meeting Banner
Abstract #2015

Diffusion Weighted Imaging (DWI) of Non-Hodgkin Lymphoma (NHL) Patients Refractory to Previous Treatment(S): Preliminary Results

Hamed Mojahed1, Thorsten Persigehl2, Owen A. O'Connor3, Ahmed Sawas3, Truman R. Brown4, Fernando Arias-Mendoza2

1Department of Biomedical Engineering, Columbia University, New York, NY, United States; 2Department of Radiology, Columbia University, New York, NY, United States; 3NYU Cancer Institute, NYU Langone Medical Center, New York University, New York, NY, United States; 4Center for Advanced Imaging Research (CAIR), Medical University of South Carolina, United States

Apparent diffusion coefficient (ADC) of Non-Hodgkin Lymphoma (NHL) refractory to the previous treatments and a newly diagnosed NHL were assessed by diffusion weighted imaging at a 1.5T Philips MR scanner. In our study ADC of refractory NHL did not show significant difference compared to normal lymph nodes in healthy volunteers. This is different than an earlier report where newly diagnosed NHL had significantly lower ADC than normal lymph nodes. However, ADC of our newly diagnosed NHL was similar to the literature. Thus, a differentiation between malignant and normal lymph nodes was not achievable by quantitative ADC evaluations for refractory NHL.